U.S. Pharmacist

Advertisement
Advertisement

Name Change for Heartburn Drug

By Staff


4/19/2010

US Pharm
. 2010;35(4):6.

Silver Spring, MD —The FDA has approved a name change for Kapidex (dexlansoprazole) to avoid confusion with two other medications. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant. Since Kapidex was approved in January 2009, there have been reports of dispensing errors due to confusion with the drugs Casodex (bicalutamide) and Kadian (morphine sulfate), which have very different uses. Kapidex is a proton pump inhibitor used to treat heartburn; Casodex, marketed by AstraZeneca, is used to treat advanced prostate cancer; and Kadian, distributed by Actavis Kadian LLC, is an opioid analgesic used to treat pain. There will be no changes made to Kapidex other than its name.

To comment on this article, contact editor@uspharmacist.com.
Advertisement

U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Copyright © 2000 - 2014 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.